Research Advances on Targeted Therapy for Acute Myeloid Leukemia--Review.
10.7534/j.issn.1009-2137.2016.01.047
- Author:
Hai-Tao HE
1
;
Hui-Min LI
2
Author Information
1. Department of Hematology, The First Affiliated Hospital, Kunming Medical University, Kunming 656032, Yunnan Province, China.
2. Department of Hematology, The First Affiliated Hospital, Kunming Medical University, Kunming 656032, Yunnan Province, China. E-mail: lihuimin@medmail.com.cn.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
therapeutic use;
DNA Modification Methylases;
antagonists & inhibitors;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
Mutation;
Prognosis;
Protein Kinase Inhibitors;
therapeutic use;
Remission Induction
- From:
Journal of Experimental Hematology
2016;24(1):245-249
- CountryChina
- Language:Chinese
-
Abstract:
Although the traditional chemotherapy has achieved a certain effect for patients with acute myeloid leukemia (AML), but there are still limitations in terms of improving the rate of complete remission and overcome relapse after remission. The further study found that many cytogenetic molecular and epigenetic abnormalities occurred during the progression of AML, such as abnormal expression of cell surface molecules, mutation, gene aberrant methylation and so on. The drugs targeted at these changes can improve the prognosis for patients, and provide a new way for treating patients with AML. At present, the mostly targeted drugs include monoclonal antibodies CD33-Ab, tyrosine kinase inhibitor, inhibitors of DNA methyltransferases inhibitors and so on. In this review, the progress of targeted therapy in AML treatment is summarized.
